Ingenuity Systems and Affymetrix Partner
News Apr 08, 2013
Ingenuity® Systems and Affymetrix®, Inc. announced that they will co-promote Ingenuity® iReport™ with Affymetrix expression microarray products effectively eliminating a bottleneck for researchers working with human, mouse and rat applications by coupling a fast and accurate statistical analysis and biological interpretation workflow with the gold-standard platform for gene expression studies.
Affymetrix expression microarrays are the standard methodology used for many research and discovery applications and when combined with Ingenuity iReport, an interactive web-based report that leverages the Ingenuity Knowledge Base of biological and chemical findings from the peer reviewed literature and databases, deliver researchers a 'sample to insight' continuous workflow allowing for rapid, confident interpretation of results without the need for bioinformatics experience or support.
"We are excited to partner with Ingenuity Systems to provide our array users with access to the intuitive biological and statistical analysis platform offered by iReport," said Kevin Cannon, Ph.D., SVP - Expression Business Unit at Affymetrix. "Bundling together our robust expression microarrays with the iReport platform will provide Affymetrix' customers with a simple and accurate tool to convert data into biologically relevant results."
"By leveraging Ingenuity iReport with Affymetrix gene expression arrays for our study on a mouse model of Familial Hypertrophic Cardiomyopathy, we accelerated our data interpretation several-fold compared to using other analysis tools.Their rapid and effectively-blind analysis provided an unbiased validation of our data. Additionally, iReport allowed us to identify and explore genes of interest found with Affymetrix gene chips, yet not identified by other analysis tools," said Adrian Grimes, Ph.D., from the Department of Pediatrics at the University of Wisconsin.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE